PyrAmes is a digital health company focused on fundamentally transforming the delivery of healthcare through continuous blood pressure monitoring that is accurate, wireless, and noninvasive. The comfort and ease of use of its platform has the potential to provide better blood pressure management for patients ranging from newborns to seniors. The FDA has recognized the company’s lead product Boppli™ with Breakthrough Device Designation. Products based on PyrAmes technology are under development and have not yet been cleared by the FDA for distribution.
PyrAmes is our third Innovation Fund investment, and they’re dedicated to finding solutions to help babies born too soon and treatments for pregnant moms at risk for conditions like preeclampsia.
PyrAmes Health recently obtained FDA approval for their Boppli product as a 510(k) Class II medical device. Boppli is used to continuously and non-invasively monitor blood pressure in neonates. The organization was awarded a third phase grant in the National Institute of Health’s RADx Maternal Health Challenge. PyrAmes is now eligible to compete in the final round of awards in early 2024.
If you have any questions about our Innovation Fund or would like to learn more about companies like PryAmes, please reach out to Eric Schaefer at [email protected].
Additional information